Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling
Open Access
- 13 March 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 29 (10), 1893-1900
- https://doi.org/10.1093/carcin/bgn158
Abstract
Tissue transglutaminase (TG2), an enzyme involved in protein cross-linking and overexpressed in ovarian tumors, has antiapoptotic effects in cancer cells and may play a role in response to chemotherapy. In this study, we investigated the role of TG2 in the sensitivity of ovarian cancer cells to cisplatin. By using stable knockdown and overexpression strategies, we demonstrate that the level of expression of TG2 regulates apoptosis induced by cisplatin in SKOV3 and OV-90 ovarian cancer cells. Interestingly, not only TG2 knockdown but also a TG2 enzymatic inhibitor (KCC009) sensitized SKOV3 cells to cisplatin. To understand the mechanism by which TG2 exerts its antiapoptotic role, we examined the effects of protein kinase B (Akt) and nuclear factor-kappa B (NF-κB), two survival pathways commonly involved in development of drug resistance. Overexpression of the constitutively active p65 subunit of NF-κB, but not constitutively active Akt, rescued cells with diminished TG2 expression from cisplatin-induced apoptosis. This implicates activation of NF-κB as the main cisplatin resistance mechanism downstream of TG2. Indeed, NF-κB activity is decreased and the level of the inhibitory subunit IκBα is increased in ovarian cancer cells engineered to express diminished levels of TG2 or treated with the enzymatic inhibitor, KCC009. Our data show that TG2 prevents apoptosis induced by cisplatin by activating the NF-κB survival pathway in ovarian cancer cells.Keywords
This publication has 34 references indexed in Scilit:
- Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer CellsClinical Cancer Research, 2008
- In Vivo Transglutaminase Type 1 Expression in Normal Lung, Preinvasive Bronchial Lesions, and Lung CancerAmerican Journal of Respiratory Cell and Molecular Biology, 2003
- Transglutaminases: crosslinking enzymes with pleiotropic functionsNature Reviews Molecular Cell Biology, 2003
- Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.2003
- Gene expression in epithelial ovarian carcinomaOncogene, 2002
- Tissue Transglutaminase Protects against Apoptosis by Modifying the Tumor Suppressor Protein p110 RbJournal of Biological Chemistry, 2002
- Tissue transglutaminase expression in breast carcinomas.2001
- XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.2001
- Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor αPublished by Elsevier BV ,2001
- Tissue Transglutaminase Is an Integrin-Binding Adhesion Coreceptor for FibronectinThe Journal of cell biology, 2000